Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01187563 · ClinicalTrials.gov registry record
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 16
- Enrollment target
NCT01187563: Completed study, sponsored by Regeneron Pharmaceuticals.
NCT01187563 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01187563 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
This is an open-label, uncontrolled, observational study in patients with rheumatoid arthritis (RA) who are receiving tocilizumab concomitantly with methotrexate as part of their standard of care.
Primary Outcome
Proportion of patients with neutropenia, elevated transaminase, and/or decreased platelet count
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-08 |
| Est. Completion | 2010-12 |
What the finished NCT01187563 record still lists
NCT01187563 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01187563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01187563 about?
NCT01187563 is a clinical study titled "A Study of Tocilizumab in Patients With Rheumatoid Arthritis". This is an open-label, uncontrolled, observational study in patients with rheumatoid arthritis (RA) who are receiving tocilizumab concomitantly with methotrexate as part of their standard of care.
What is the current status of trial NCT01187563?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2010-08. Estimated completion is 2010-12.
Who is sponsoring clinical trial NCT01187563?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia